Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Clinical ShowCase™: Applying the Evidence to Case Scenarios in Relapsed/Refractory Multiple Myeloma

Release Date: October 28, 2021
Expiration Date: October 28, 2022

Activity Overview

This online activity is designed to provide concise and easy-to-digest education on diagnosis and treatment selection for newly diagnosed and relapsed/refractory multiple myeloma (RR MM) in an engaging, interactive, case-based format. The multimedia format of this program includes interactive clinical decision points with explanations at the end of the activity and an evidence-based review supporting the teaching points covered in the case.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

The activity is directed toward medical oncologists and hematologist/oncologists who treat or manage patients with multiple myeloma. Pathologists, fellows, nurses, nurse practitioners, physician assistants, pharmacists and other healthcare professionals interested in the treatment or management of multiple myeloma are also invited to participate in the online activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Explain the impact of disease-specific factors, risk assessment, and treatment history on therapy decisions in MM across lines of care.
Assess the safety and efficacy profiles of current and emerging therapies for patients with MM across treatment lines.
Employ strategies to monitor and minimize the negative impact of treatment-related toxicities in patents with MM.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Faculty

Giada Bianchi, MD
Associate Director, Amyloidosis Program
Brigham and Women’s/Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Other: Pfizer advisory board participation.

Matthew Ho, MB BCh, BAO, PhD

Matthew Ho, MB BCh, BAO, PhD
Internal Medicine-Heme/Oncology Physician Scientist Resident
Department of Medicine
Mayo Clinic
Rochester, MN

Disclosures: Matthew Ho, MB, BCh, BAO, PhD has no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.